6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00200525 (ClinicalTrials.gov)	July 2001	13/9/2005	Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease	A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing-Off Effects Associated With Late-Stage PD After Apomorphine Use	Parkinson Disease	Drug: apomorphine HCl injection	Mylan Bertek Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	60	Phase 3	NULL
2	NCT00145171 (ClinicalTrials.gov)	February 2001	2/9/2005	A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.	Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.	Parkinson Disease	Drug: apomorphine HCl injection	Mylan Bertek Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	56	Phase 3	NULL
3	NCT00200512 (ClinicalTrials.gov)	September 1999	13/9/2005	Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months	A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing Off Effects Associated With Late Stage Parkinson's Disease	Parkinson Disease	Drug: apomorphine HCl injection	Mylan Bertek Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	16	Phase 2/Phase 3	United Kingdom
4	NCT00142545 (ClinicalTrials.gov)	July 1999	31/8/2005	Long Term Safety and Efficacy of SC Apomorphine in Treatment of Off Episodes in Late-Stage Parkinson's Disease	Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off” Episodes in Patients With On-Off” or Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease	Parkinson Disease	Drug: apomorphine HCl injection	Mylan Bertek Pharmaceuticals	NULL	Completed	18 Years	N/A	Both	800	Phase 3	United States